Zaloguj się

Gotowe bibliografie tematyczne / Non-small cell lung cancer / Artykuły w czasopismach

Artykuły w czasopismach na temat „Non-small cell lung cancer”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Non-small cell lung cancer.

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 1 czerwca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Non-small cell lung cancer”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Cheng, Wenhan, M. D, MS c, Eldon Brown, MS c, Matt Gorman, B. S, Timothy Babushok, M. D i PH D. "Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer". International Journal of Medical Reviews and Case Reports 4, Reports in Clinical Medicine and (2020): 1. http://dx.doi.org/10.5455/ijmrcr.atezolizumab-non-small-cell-lung-cancer.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Hellriegel, H. "ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY". Siberian Medical Review, nr 6 (2017): 6–12. http://dx.doi.org/10.20333/2500136-2017-6-12.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Klaus-Peter, K. "ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY". Siberian Medical Review, nr 6 (2017): 6–12. http://dx.doi.org/10.20333/2500136-2017-6-6-12.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

_, _. "Non–Small Cell Lung Cancer". Journal of the National Comprehensive Cancer Network 6, nr 3 (marzec 2008): 228. http://dx.doi.org/10.6004/jnccn.2008.0021.

Pełny tekst źródła

Streszczenie:

Lung cancer is the leading cause of cancer-related death in both men and women in the United States. An estimated 213,380 new cases (114,760 men and 98,620 women) of lung and bronchus cancer will be diagnosed in 2007, and 160,390 deaths (89,510 in men, 70,880 in women) are estimated to occur because of the disease. Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancer cases and includes 3 major types: (1) adenocarcinoma; (2) squamous cell (epidermoid) carcinoma; and (3) large-cell carcinoma. Adenocarcinoma is the most common type of lung cancer seen in the United States and is also the most frequently occurring cell type in nonsmokers. Important updates to the 2008 guidelines on NSCLC include the addition of tables on drugs and dosing information on chemotherapy regimens for adjuvant therapy. For the most recent version of the guidelines, please visit NCCN.org

Style APA, Harvard, Vancouver, ISO itp.

5

Skřičková, Jana, Bohdan Kadlec i Ondřej Venclíček. "Non-small cell lung cancer". Vnitřní lékařství 63, nr 11 (1.11.2017): 861–74. http://dx.doi.org/10.36290/vnl.2017.159.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Ettinger, David S., Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac i in. "Non–Small Cell Lung Cancer". Journal of the National Comprehensive Cancer Network 8, nr 7 (lipiec 2010): 740–801. http://dx.doi.org/10.6004/jnccn.2010.0056.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Ettinger, David S., Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico i in. "Non–Small Cell Lung Cancer". Journal of the National Comprehensive Cancer Network 10, nr 10 (październik 2012): 1236–71. http://dx.doi.org/10.6004/jnccn.2012.0130.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Fromer, Margot J. "Non-Small-Cell Lung Cancer". Oncology Times 30, nr 4 (luty 2008): 21–25. http://dx.doi.org/10.1097/01.cot.0000313049.69678.f6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Hill, A., P. Fisher i D. Yeomanson. "Non-small cell lung cancer". BMJ 345, sep27 1 (27.09.2012): e6443-e6443. http://dx.doi.org/10.1136/bmj.e6443.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Cox, James D. "Non-small Cell Lung Cancer". Chest 89, nr 4 (kwiecień 1986): 284S—288S. http://dx.doi.org/10.1378/chest.89.4_supplement.284s.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Pearson, F. Griffith. "Non-small Cell Lung Cancer". Chest 116 (grudzień 1999): 500S—503S. http://dx.doi.org/10.1378/chest.116.suppl_3.500s.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

Held-Warmkessel, Jeanne, i Linda Schiech. "Non-small cell lung cancer". Nursing 44, nr 2 (luty 2014): 32–42. http://dx.doi.org/10.1097/01.nurse.0000441877.57254.95.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

&NA;. "Non-small cell lung cancer". Nursing 44, nr 2 (luty 2014): 42–43. http://dx.doi.org/10.1097/01.nurse.0000441878.64877.76.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Haskell, Charles M., i E. Carmack Holmes. "Non-small cell lung cancer". Current Problems in Cancer 11, nr 1 (styczeń 1987): 1–52. http://dx.doi.org/10.1016/s0147-0272(87)80002-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Dediu, M., i W. Hilbe. "Non-small cell lung cancer". memo - Magazine of European Medical Oncology 1, nr 4 (grudzień 2008): 247–51. http://dx.doi.org/10.1007/s12254-008-0068-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Haskell, Charles M., i E. Carmack Holmes. "Non-small cell lung cancer". Disease-a-Month 34, nr 2 (luty 1988): 55–108. http://dx.doi.org/10.1016/0011-5029(88)90024-7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Goldstraw, Peter, David Ball, James R. Jett, Thierry Le Chevalier, Eric Lim, Andrew G. Nicholson i Frances A. Shepherd. "Non-small-cell lung cancer". Lancet 378, nr 9804 (listopad 2011): 1727–40. http://dx.doi.org/10.1016/s0140-6736(10)62101-0.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Frei, Emil. "Non-small Cell Lung Cancer". Chest 112, nr 4 (październik 1997): 266S—268S. http://dx.doi.org/10.1378/chest.112.4_supplement.266s.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Vokes, Everett E., i Jacob D. Bitran. "Non-Small-Cell Lung Cancer". Chest 106, nr 3 (wrzesień 1994): 659–61. http://dx.doi.org/10.1378/chest.106.3.659.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Sause, William T. "Non-small cell lung cancer". International Journal of Radiation Oncology*Biology*Physics 42, nr 1 (styczeń 1998): 110. http://dx.doi.org/10.1016/s0360-3016(98)80061-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

Pearson, F. Griffith. "The role of adjuvant therapy in completely resected, non-small cell lung cancer". Journal of the Japanese Association for Chest Surgery 19, nr 3 (2005): 272–73. http://dx.doi.org/10.2995/jacsurg.19.272.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

Greschuchna, D. "Surgical Treatment of Small Cell Lung Cancer". Journal of the Japanese Association for Chest Surgery 3, nr 2 (1989): 169. http://dx.doi.org/10.2995/jacsurg1987.3.2_169.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Kurata, Takayasu, Isamu Okamoto, Kenji Tamura i Masahiro Fukuoka. "Amrubicin for non-small-cell lung cancer and small-cell lung cancer". Investigational New Drugs 25, nr 5 (13.07.2007): 499–504. http://dx.doi.org/10.1007/s10637-007-9069-0.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Beattie, Edward J., i Noel M. Raskin. "Progress in lung cancer: Non-oat cell (non-small cell lung cancer)". Japanese Journal of Surgery 17, nr 5 (wrzesień 1987): 313–22. http://dx.doi.org/10.1007/bf02470629.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Ming, Zhang. "Effects and mechanism of anlotinib on radiosensitivity of non-small cell lung cancer cell lines a549". Journal of Medical pharmaceutical and allied sciences 12, nr 6 (29.12.2023): 6223–29. http://dx.doi.org/10.55522/jmpas.v12i6.5821.

Pełny tekst źródła

Streszczenie:

To investigate the effect and mechanism of Anlotinib on radio sensitization of human lung adenocarcinoma cell line A549. Human lung adeno carcinoma cell line A549 was teated with anlotinib and/or radiotherapy, then divided four groups, control group (Ctrl), Anlotinib treatment group (A), irradiation group (RT) and Anlotinib combined with irradiation group (A+RT) . CCK8 method was used to determine cell proliferation; the clone formation experiment was used to determine the inhibitory effect on cell growth; flow cytometry was used to determine cell cycle and apoptosis; immunofluorescence of γ-H2AX was used to determine DNA damage; expression of DNA-PKcs were detected by Western blot. Anlotinib inhibited proliferation and clonogenic survival following irradiation. The dose (Dq), the average lethal dose (D0) and the survival score (SF2) in the anlotinib combined radiotherapy group was significantly lower than those in the radiotherapy group. Anlotinib decreased G2/M phase arrest and promoted the cells apoptosis induced by in irradiation. The confocal microscopy results showed the average number of γ-H2AX foci in the A+RT group was more than that in RT group. The protein levels of DNA-PKcs were higher in A+RT group than that in RT group. Anlotinib enhances the radio sensitivity of A549 cells, which may be attributed to the delay DNA damage repair. It provides a rationale strategy by Anlotinib combined with irradiation for NSCLC.

Style APA, Harvard, Vancouver, ISO itp.

26

Kalkan, Fatih, i Mehmet Özler. "DELTA-9 TETRAHYDROCANNABINOID AND GEMSITABIN COMBINATION ON NON-SMALL CELL (SQUAMOUS CELL, SK-MES-1) LUNG CANCER CELL LINE". Era's Journal of Medical Research 10, nr 01 (czerwiec 2023): 1–12. http://dx.doi.org/10.24041/ejmr2023.1.

Pełny tekst źródła

Streszczenie:

Squamous cell carcinoma falls within the category of non-small cell lung cancers, presenting a considerable challenge in terms of treatment management. There has been growing interest in the potential anti-cancer properties of Delta-9 tetrahydrocannabinol. Gemcitabine, a nucleoside analog, has shown effectiveness against diverse cancer types. This study aimed to assess the combined efficacy of Delta-9 tetrahydrocannabinol and Gemcitabine in treating cancer. The squamous lung cancer cell line required for our study was provided by the stem cell unit. The doses were determined as 5µm/L and 10µm/L for Delta-9 tetrahydrocannabinol, 20 and 40 µm/Lfor Gemcitabine by performing a literature review. In our study, CellViabilityAnalysis by MTT, Xcelligence Real-Time Cell Analysis, Annexin V Apoptosis Flow Cytometry Analysis, Total Oxidant, Antioxidant Status, and Caspase-3 Detection Analysis was performed. Upon evaluating the rates of apoptotic cell death, it was observed that the THC 5 and THC 10 treatment groups exhibited a 30% and 60% increase, respectively, compared to the alcohol group. A significant difference in cytotoxic effect, as determined by MTT, was found between the control group and the Gemsitabin 20, Delta-9 Tetrahydrocannabinol 5µm/L, and Gemsitabin 20+Delta-9 Tetrahydrocannabinol 5µm/L groups (p<0.001). There was a statistically significant difference between the groups regarding TOS (p<0.001). All experimental groups exhibited a higher level of caspase 3 activations, in comparison to the control group. We observed a significant cytotoxic effect of Gemcitabine on squamous cell lung cancer cells. Delta-9 tetrahydrocannabinol, when used alone, exhibited a relatively low cytotoxic effect. However, no significant difference was observed in the groups where Delta-9 tetrahydrocannabinolwas combined with Gemcitabine.

Style APA, Harvard, Vancouver, ISO itp.

27

Varker, Kimberly A. "Small- and non-Small- Cell Lung Cancer". Guthrie Journal 70, nr 1 (styczeń 2001): 2–8. http://dx.doi.org/10.3138/guthrie.70.1.002.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

Laera, Letizia, i Silvia Novello. "Immunotherapy and non-small cell lung cancers". Cancer Breaking News 5, nr 3 (15.12.2017): 6–10. http://dx.doi.org/10.19156/cbn.2017.0052.

Pełny tekst źródła

Streszczenie:

Lung cancer is the leading cause of cancer mortality, and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Immunotherapy has brought a paradigm shift to the treatment of NSCLC. Immune checkpoint inhibitors have emerged as one of the main new therapeutic options for patients with advanced NSCLC. This brief review focuses on analyzing the biological rationale and early clinical data available concerning immunotherapeutic strategies, and more specifically, programmed cell death-1 (PD-1) inhibitors and programmed cell death-ligand 1 (PD-L1) inhibitors.

Style APA, Harvard, Vancouver, ISO itp.

29

Tavartkiladze, Alexandre, Revaz Turmanidze, Gaiane Simonia, Margalita Gogoladze, Pati Revazishvili, George Dundua i Irine Andronikashvili. "Circulating Tumor Cells and cfDNA: Key Predictive Biomarkers in Non - Small Cell Lung Cancer Progression and Treatment". International Journal of Science and Research (IJSR) 12, nr 10 (5.10.2023): 1078–81. http://dx.doi.org/10.21275/sr231013031834.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Deniz, Özdemir. "KAN0438757: A NOVEL PFKFB3 INHIBITOR THAT INDUCES PROGRAMMED CELL DEATH AND SUPPRESSES CELL MIGRATION IN NON-SMALL CELL LUNG CARCINOMA CELLS". Biotechnologia Acta 16, nr 5 (31.10.2023): 34–44. http://dx.doi.org/10.15407/biotech16.05.034.

Pełny tekst źródła

Streszczenie:

Aim. PFKFB3 is glycolytic activators that is overexpressed in human lung cancer and plays a crucial role in multiple cellular functions including programmed cell death. Despite the many small molecules described as PFKFB3 inhibitors, some of them have shown disappointing results in vitro and in vivo. On the other hand KAN0438757, selective and potent, small molecule inhibitor has been developed. However, the effects of KAN0438757, in non-small cell lung carcinoma cells remain unknown. Herein, we sought to decipher the effect of KAN0438757 on proliferation, migration, DNA damage, and programmed cell death in non-small cell lung carcinoma cells. Methods. The effects of KAN0438757 on cell viability, proliferation, DNA damage, migration, apoptosis, and autophagy in in non-small cell lung carcinoma cells was tested by WST-1, real-time cell analysis, comet assay, wound-healing migration test, and MMP/JC-1 and AO/ER dual staining assays as well as western blot analysis. Results. Our results revealed that KAN0438757 significantly suppressed the viability and proliferation of A549 and H1299 cells and inhibited migration of A549 cells. More importantly, KAN0438757 caused DNA damage and triggered apoptosis and this was accompanied by the up-regulation of cleaved PARP in A549 cells. Furthermore, treatment with KAN0438757 resulted in increased LC3 II and Beclin1, which indicated that KAN0438757 stimulated autophagy. Conclusions. Overall, targeting PFKFB3 with KAN0438757 may be a promising effective treatment approach, requiring further in vitro and in vivo evaluation of KAN0438757 as a therapy in non-small cell lung carcinoma cells.

Style APA, Harvard, Vancouver, ISO itp.

31

Adelstein, David J., Joseph F. Tomashefski, Norman J. Snow, Terrence P. Horrigan i John D. Hines. "Mixed Small Cell and Non-Small Cell Lung Cancer". Chest 89, nr 5 (maj 1986): 699–704. http://dx.doi.org/10.1378/chest.89.5.699.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Mangum, M. D., F. A. Greco, J. D. Hainsworth, K. R. Hande i D. H. Johnson. "Combined small-cell and non-small-cell lung cancer." Journal of Clinical Oncology 7, nr 5 (maj 1989): 607–12. http://dx.doi.org/10.1200/jco.1989.7.5.607.

Pełny tekst źródła

Streszczenie:

Nine (2%) of 429 small-cell lung cancer (SCLC) patients seen at Vanderbilt University between 1977 and 1983 had a combined subtype SCLC at diagnosis (ie, small-cell carcinoma plus squamous cell or adenocarcinoma). Staging procedures and chemotherapy treatment were uniform for all 429 patients. The diagnosis of combined histology was established via bronchoscopy (six patients), needle aspiration biopsy (one), lymph node biopsy (one), and thoracotomy (one). The clinical characteristics of the combined subtype patients were similar to patients with other subtypes of SCLC (ie, there were no differences in median age, sex, performance status, and stage of disease). However, patients with a combined subtype histology had a higher incidence of peripheral lesions on chest x-ray (56% v 14%, P less than .001) and a lower median lactate dehydrogenase (LDH) (301 IU/L v 341 IU/L, P = .0002) at diagnosis. The overall response to chemotherapy (57% v 78; P = .5) and the median survival (8 months v 10 months; P = .4) of the combined subtype patients were similar to patients with other subtypes of SCLC. Two (22%) combined histology patients survived greater than or equal to 5 years. Both had had surgical resection in addition to chemotherapy. These data suggest that the combined subtype of SCLC is clinically similar to pure SCLCs and that surgery may play a prominent role in the management of these tumors. The possibility of a combined histology tumor should be considered in patients thought to have SCLC on the basis of limited biopsy material, such as a needle aspiration or bronchial biopsy, and when the primary lesion is peripherally located on chest x-ray.

Style APA, Harvard, Vancouver, ISO itp.

33

Kobayashi, Kunihiko. "4) Non-small Cell Lung Cancer". Nihon Naika Gakkai Zasshi 101, Suppl (2012): 110c—111a. http://dx.doi.org/10.2169/naika.101.110c.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

34

Kobayashi, Kunihiko. "3) Non-small Cell Lung Cancer". Nihon Naika Gakkai Zasshi 101, nr 9 (2012): 2520–25. http://dx.doi.org/10.2169/naika.101.2520.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

Yasufuku, Kazuhiro, i Shaf Keshavjee. "Staging Non–Small Cell Lung Cancer". Clinical Pulmonary Medicine 17, nr 5 (wrzesień 2010): 223–31. http://dx.doi.org/10.1097/cpm.0b013e3181ef721c.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

Rossi, Giulio, Giuseppe Pelosi, Mattia Barbareschi, Paolo Graziano, Alberto Cavazza i Mauro Papotti. "Subtyping Non–Small Cell Lung Cancer". International Journal of Surgical Pathology 21, nr 4 (5.06.2013): 326–36. http://dx.doi.org/10.1177/1066896913489346.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

Quint, Leslie Eisenbud. "Staging non-small cell lung cancer". Cancer Imaging 7, nr 1 (2007): 148–59. http://dx.doi.org/10.1102/1470-7330.2007.0026.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Baron, M. Gonzalez, C. Garcia Giron, P. Zamora, M. L. Garcia de Parades, J. Feliu, A. Ordoñez, A. Artal, P. Garrido i J. I. Chacon. "Non-Small-Cell Lung Cancer (NSCLC)". American Journal of Clinical Oncology 15, nr 1 (luty 1992): 23–28. http://dx.doi.org/10.1097/00000421-199202000-00005.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Laskin, Janessa J., Alan B. Sandler i David H. Johnson. "Introduction: Non-Small Cell Lung Cancer". Seminars in Oncology 32, nr 3 (czerwiec 2005): 251–52. http://dx.doi.org/10.1053/j.seminoncol.2005.04.014.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

KOYAMA, RYO, i KAZUHISA TAKAHASHI. "Non-Small-Cell Lung Cancer Treatment". Juntendo Medical Journal 62, nr 1 (2016): 7–12. http://dx.doi.org/10.14789/jmj.62.7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

Armstrong, P., i J. M. Vincent. "Staging non-small cell lung cancer". Clinical Radiology 48, nr 1 (lipiec 1993): 1–10. http://dx.doi.org/10.1016/s0009-9260(05)80099-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Palma, David A., i Gregory M. M. Videtic. "Oligometastatic Non-Small-Cell Lung Cancer". International Journal of Radiation Oncology*Biology*Physics 93, nr 2 (październik 2015): 223–26. http://dx.doi.org/10.1016/j.ijrobp.2015.07.2277.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Heist, Rebecca S., i Jeffrey A. Engelman. "SnapShot: Non-Small Cell Lung Cancer". Cancer Cell 21, nr 3 (marzec 2012): 448–448. http://dx.doi.org/10.1016/j.ccr.2012.03.007.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Sherry, Victoria. "Metastatic non—small cell lung cancer". Nurse Practitioner 41, nr 12 (grudzień 2016): 1–5. http://dx.doi.org/10.1097/01.npr.0000502795.96478.bb.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Sherry, Victoria. "Metastatic non—small cell lung cancer". Nurse Practitioner 41, nr 12 (grudzień 2016): 1–5. http://dx.doi.org/10.1097/01.npr.0000511092.91174.b4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Luciani, Andrea. "NON SMALL CELL LUNG CANCER (NSCLC)". Journal of Geriatric Oncology 5 (październik 2014): S2—S3. http://dx.doi.org/10.1016/j.jgo.2014.09.006.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

Edelman, Martin J., i Shyam L. Khanwani. "Advanced non-small cell lung cancer". Current Treatment Options in Oncology 2, nr 1 (styczeń 2001): 51–62. http://dx.doi.org/10.1007/s11864-001-0016-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Sause, William. "310 Non-small cell lung cancer". International Journal of Radiation Oncology*Biology*Physics 39, nr 2 (styczeń 1997): 126. http://dx.doi.org/10.1016/s0360-3016(97)80529-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Renaud, Stéphane, Michèle Beau-Faller i Gilbert Massard. "KRASin Non–Small-Cell Lung Cancer". JAMA Oncology 2, nr 10 (1.10.2016): 1373. http://dx.doi.org/10.1001/jamaoncol.2016.2350.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

Ettinger, David S. "Metastatic non-small cell lung cancer". Lung Cancer 9 (sierpień 1993): 69–79. http://dx.doi.org/10.1016/0169-5002(93)90172-t.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!